Biosplice’s lorecivivint, which may slow rather than mask knee osteoarthritis, has entered formal review with UK’s MHRA ahead of EU filing.
Ask anyone who’s watched a parent stop gardening, or gradually give up stairs, what osteoarthritis actually costs a person, and cartilage loss is rarely the first thing they mention. It’s the shrinking of a life, fewer walks, skipped grandkids’ soccer games, a slow retreat from independence. That’s the backdrop against which Biosplice Therapeutics is trying to bring the first potentially disease-modifying drug for knee osteoarthritis to market, and this month it cleared an important, if unglamorous, hurdle.
The San Diego-based biopharmaceutical company announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its application for lorecivivint, known as LOR, as complete and valid, formally starting the MHRA’s review timetable. Biosplice plans to file a parallel application with the European Medicines Agency later this month [1].
A shot instead of a Band-Aid
Most current osteoarthritis treatments manage pain without touching the underlying joint damage. Lorecivivint is different, at least on paper. It’s a small-molecule suspension injected directly into the knee joint, as infrequently as once a year, that Biosplice believes can slow or reverse structural damage rather than just numbing the symptoms of it.
The mechanism, stripped of its chemistry, comes down to two targets. The drug inhibits DYRK1A, an inflammatory enzyme, which appears to reduce the inflammatory signals and cartilage-degrading enzymes that erode joint tissue over time. It also inhibits CLK2, which affects a cell-signaling pathway believed to help cartilage-producing cells regenerate and protect the joint’s hyaline cartilage, the smooth tissue that lets bones glide instead of grind.
Across eleven clinical trials, Biosplice says LOR has shown a safety profile similar to placebo, helped in part by the fact that an intra-articular injection stays largely local and doesn’t circulate systemically through the body. The strongest evidence for disease modification came from the Phase 3 OA-07 trial, where imaging tracked medial joint space width, essentially a measure of how much cartilage cushion remains between bones, and it’s the standard clinicians use to gauge whether a joint is structurally deteriorating.
Patients on LOR maintained, and in some cases improved, that joint space over two years of annual injections. Placebo patients lost joint space during year one, but interestingly, once they crossed over to active treatment, they too showed gains, a detail that adds weight to the case that the drug is doing something structural rather than just easing symptoms. Pain scores improved by six months, with both pain and function improving by twelve months compared with placebo, echoing results already seen in earlier Phase 2 trials.
What’s actually at stake
“After more than a decade of clinical development and eleven clinical trials, lorecivivint is now formally under assessment in the United Kingdom,” said Biosplice CEO Erich Horsley. “As many knee OA patients are aware, the patient journey for someone diagnosed with knee OA is currently painful and disheartening. Patients have gone decades without a meaningful new treatment option, and this assessment could be an important step towards dramatically improving the quality and duration of millions of patient lives.”
Louis Tharp, executive director of the patient advocacy group Global Healthy Living Foundation and its CreakyJoints community, put it in more personal terms: “We hear constantly from osteoarthritis patients who await safe, innovative and potentially disease-modifying medicines to treat OA. The UK’s review of LOR for approval brings hope to millions of long-suffering patients.”
The scale of that hope is worth pausing on. Osteoarthritis affects an estimated 50 million adults in the U.S. and more than 500 million worldwide, with roughly 1 in 10 American adults living with knee OA specifically. About half of symptomatic knee cases show up by age 55, well before most people consider themselves “old.” Around 80% of people with OA report some functional limitation, and a quarter can’t manage major daily activities at all. Mortality is even higher among people with knee and hip OA, largely because reduced mobility drags cardiovascular health down with it, which is precisely why the FDA now classifies knee OA as a serious condition rather than a routine one.
That mobility-longevity link is easy to overlook next to flashier science, but it’s real: staying able to walk, climb stairs and stay active is one of the strongest predictors of a longer, healthier life. If lorecivivint clears MHRA and EMA review on the strength of the data behind it, it wouldn’t just ease pain. It could help keep millions of aging joints, and the people attached to them, moving.
